maximus glp 1 microdose Microdosing GLP1's is going mainstream Safety Information forProactive HealthMicrodose GLP-1Rx

Prescribing information and publications from PIONEER trials related to Oral Semaglutide (Rybelsus)

It can be found in a mysterious corner of the world somewhere

Sometimes a second agent can be rational

Compared to the control group, GLP-1RAs were associated with significant reductions in weight (mean difference (MD) = -5.70 kg, 95% confidence interval (CI): -9.52 to -1.88), BMI (MD = -2.94 kg/m 2 , 95% CI: -5.60 to -0.28), WC (MD = -3.66 cm, 95% CI: -4.89 to -2.43), glycated hemoglobin A1c (HbA1c) (standardized mean difference (SMD) = -0.73, 95% CI: -1.14 to -0.32), and systolic blood pressure (SBP) (MD = -3.62 mm Hg, 95% CI: -5.51 to -1.73) after cessation of therapy

doi:10.1186/1475-2840-12-125 17

This further substantiates the potential of therapies targeting the PYY system in the treatment of obesity